×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Yahoo Movies UK
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to...
7 hours ago
aTyr Pharma to Present at Upcoming Investor Conferences
Yahoo Finance
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the...
4 days ago
aTyr Pharma to Participate in April Investor Conferences
GlobeNewswire
(Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...
1 month ago
Atyr Pharma: Q1 Earnings Snapshot
Houston Chronicle
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (LIFE) on Thursday reported a loss...
1 week ago
HC Wainwright Reaffirms “Buy” Rating for aTyr Pharma (NASDAQ:LIFE)
Defense World
Read HC Wainwright Reaffirms “Buy” Rating for aTyr Pharma (NASDAQ:LIFE) at Defense World.
3 days ago
aTyr Pharma reports Q1 EPS (23c), consensus (24c) - TipRanks.com
Tipranks
Reports Q1 revenue $235K, consensus $20K…Cash, cash equivalents, restricted cash and investments as of March 31 , were $87.7M. Based on the...
6 days ago
Bullish aTyr Pharma Insider Buying Worth US$514.6k Yet To Pay Off
Simply Wall Street
Insiders who bought US$514.6k worth of aTyr Pharma, Inc.'s ( NASDAQ:LIFE ) stock at an average buy price of US$2.10...
3 weeks ago
aTyr Pharma doses first patient in systemic sclerosis trial
Clinical Trials Arena
aTyr Pharma has dosed the first subject in the Phase II EFZO-CONNECT trial of efzofitimod to treat systemic sclerosis (ILD).
6 months ago
Atyr Pharma: Q4 Earnings Snapshot
Quartz
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (LIFE) on Thursday reported a loss of $14.8 million in its fourth quarter.
1 month ago
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
Yahoo Finance
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024.
1 week ago